REAL-WORLD UTILISATION AND CLINICAL OUTCOMES OF PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER TREATED WITH OLAPARIB IN THE FIRST-LINE MAINTENANCE SETTING: 2-YEAR CLINICAL OUTCOMES OF THE PAN-EUROPEAN OVAL-1 STUDY

被引：0
|
作者：
Lorusso, Domenica [1 ,2 ]
Garbay, Delphine [3 ]
Asselain, Bernard Jean Roger [4 ]
Miller, Rowan [5 ,6 ]
Raspagliesi, Francesco [7 ]
Zamagni, Claudio [8 ]
Leary, Alexandra [9 ]
Bellier, Charlotte [10 ]
Glasspool, Ros [11 ,12 ]
Jayson, Gordon [13 ,14 ]
Grevat, Emmanuelle [15 ]
Kertous, Mehdi [15 ]
Sabatucci, Ilaria [16 ]
Padrone, Claudia [16 ]
Jayia, Parveen [17 ]
Hada, Manila [18 ]
Mclaurin, Kimmie [18 ]
Gourley, Charlie [19 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Scienze Salute Donna, Bambino & Sanita Pubbl, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Clin Tivoli Ducos, Bordeaux, France
[4] ARCAGY GINECO, Paris, France
[5] Univ Coll London Hosp, London, England
[6] St Bartholomews Hosp, London, England
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
[9] Inst Gustave Roussy, Villejuif, France
[10] Ctr Oscar Lambret, Dept Cancerol Gynecol & Senol, Lille, France
[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[12] Univ Glasgow, Glasgow, Scotland
[13] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Manchester, England
[14] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth, Manchester, England
[15] AstraZeneca, Paris, France
[16] AstraZeneca, Milan, Italy
[17] AstraZeneca, London, England
[18] AstraZeneca, Oncol Outcomes Res, Global Med Affairs Evidence Generat & External Al, Gaithersburg, MD USA
[19] Univ Edinburgh, Canc Res UK Scotland Ctr, Edinburgh, Scotland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷
关键词：
D O I：
10.1136/ijgc-2023-ESGO.895
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
512
引用
收藏
页码：A426 / A426
页数：1
相关论文
共 50 条
  • [31] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
    Balmana, J.
    Fasching, P. A.
    Delaloge, S.
    Park, Y. H.
    Eisen, A.
    Bourgeois, H.
    Kemp, Z.
    Jankowski, T.
    Sohn, J.
    Aksoy, S.
    Timcheva, C. V.
    Park-Simon, T-W.
    Torres, A. Anton
    John, E.
    Baria, K.
    Walker, G.
    Gelmon, K. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S205 - S206
  • [32] Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
    Robert S. Miller
    Stella Mokiou
    Aliki Taylor
    Ping Sun
    Katherine Baria
    Breast Cancer Research and Treatment, 2022, 193 : 83 - 94
  • [33] Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
    Chase, Dana
    Perhanidis, Jessica
    Gupta, Divya
    Kalilani, Linda
    Golembesky, Amanda
    Gonzalez-Martin, Antonio
    JCO CLINICAL CANCER INFORMATICS, 2023, 7 : e2200189
  • [34] Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
    Chase, Dana
    Perhanidis, Jessica
    Gupta, Divya
    Kalilani, Linda
    Golembesky, Amanda
    Gonzalez-Martin, Antonio
    JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [35] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [36] Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
    Depenni, Roberta
    Rocca, Maria Cossu
    Ferrari, Daris
    Azzarello, Giuseppe
    Baldessari, Cinzia
    Alu, Massimiliano
    Nole, Franco
    Codeca, Carla
    Boscolo, Giorgia
    Piccininni, Marco
    Cavalieri, Stefano
    Bossi, Paolo
    EUROPEAN JOURNAL OF CANCER, 2019, 115 : 4 - 12
  • [37] Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ (R) study
    Miller, Robert S.
    Mokiou, Stella
    Taylor, Aliki
    Sun, Ping
    Baria, Katherine
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 83 - 94
  • [38] Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
    Moser, Sarah Sharman
    Apter, Lior
    Livnat, Idit
    Ginsburg, Roni
    Yarden, Adva
    Drori, Michal
    Drizon, Anat
    Chodick, Gabriel
    Siegelmann-Danieli, Nava
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 105 - 116
  • [39] Real-world clinical outcomes and prognostic factors of olaparib maintenance in Korean patients with primary or recurrent high-grade ovarian cancer with exploratory analysis of location of BRCA1 and BRCA2 mutations
    Kim, Junhwan
    Park, So-Yeon
    Kim, Ju-Hyun
    Lee, Shin-Wha
    Park, Jeong-Yeol
    Suh, Dae-Shik
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Dae-Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
    Gelmon, Karen A.
    Fasching, Peter A.
    Couch, Fergus J.
    Balmana, Judith
    Delaloge, Suzette
    Labidi-Galy, Intidhar
    Bennett, James
    McCutcheon, Susan
    Walker, Graham
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 68 - 77
12345